Aurobindo Pharma has made its brand of molnupiravir- Molnaflu available widely in India. Molnupiravir (Molnaflu) is for the treatment of adult patients with COVID-19, with Sp02 >93 per cent and who have a high risk of progression of the disease including hospitalisation or death.

Aurobindo’s brand Molnaflu is now available pan-India across all major metros and towns through its distribution partner.

Molnupiravir was earlier approved under Emergency Use Authorisation from CDSCO, India. This is the first oral antiviral approved by India, the UK agency and also by US Foods & Drugs Administration.  

Earlier last year, Aurobindo had signed a bi-lateral non-exclusive voluntary licensing agreement with Merck Sharpe Dohme, Singapore (MSD), a subsidiary of Merck & Co. (US) to manufacture and supply Molnupiravir to over 100 low and middle-income countries (LMIC), including India.

The product will be manufactured at the company’s manufacturing facilities in India that are approved by global regulatory agencies including US FDA and UKMHRA. The company has adequate capacities to meet the global demand across the 100 + LMI Countries for the product.